Neurogene nabs $115M in series B financing

By The Science Advisory Board staff writers

December 16, 2020 -- Neurogene has completed $115 million in series B financing, which will be used to advance various aspects of the company's gene therapy programs and technology.

The funds will help advance the company's collection of gene therapy programs, support novel gene therapy design, invest in the company's technology platform, and expand Neurogene's adeno-associated virus (AAV) vector good manufacturing practice manufacturing capabilities. Neurogene's lead programs use AAV vector-based gene therapy technology to treat rare, neurological diseases.

The round of financing was led by EcoR1 Capital, with participation from existing and new investors.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.